(LEGN) Legend Biotech Corporation Company Overview

What does Legend Biotech do?

Legend Biotech Corporation is a global cell-therapy company listed on the Nasdaq Global Select Market under the ticker LEGN. Its commercial center of gravity is CARVYKTI, a one-time autologous chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma. Legend develops and commercializes the product with Janssen Biotech, part of Johnson & Johnson, while building a broader pipeline in hematologic cancers, solid tumors, autoimmune disease, and in-vivo cell therapy. The company’s 2025 Form 20-F describes a Cayman Islands holding company with operating subsidiaries primarily in the United States, China, and Europe.

Why does this business matter?

Multiple myeloma remains difficult to cure, and treatment becomes harder as patients relapse. CARVYKTI matters because it has moved from a late-line rescue therapy toward earlier treatment settings, expanding the addressable population and increasing the operational importance of manufacturing capacity, treatment-center access, and physician confidence. By the first quarter of 2026, the therapy was available at more than 300 sites in 18 markets. That global footprint turns Legend from a conventional development-stage biotechnology company into a commercial cell-therapy platform whose economics increasingly depend on execution at scale.

How does Legend Biotech make money?

Legend’s reported revenue is not the same as CARVYKTI’s global net trade sales. Under the Janssen collaboration, Janssen is generally the principal seller outside Greater China, and Legend recognizes its pro-rata share of collaboration net trade sales as collaboration revenue. The partners share pre-tax profits and losses equally outside Greater China; Legend retains or bears 70% in Greater China. This accounting structure means investors must track both end-market sales and Legend’s reported collaboration revenue.

Which revenue source dominates?

The concentration is strategically attractive because CARVYKTI is growing rapidly, but it also creates dependency. A manufacturing interruption, safety concern, competitive launch, reimbursement change, or demand slowdown would affect nearly the entire revenue base. Legend’s pipeline therefore has two jobs: extend the CARVYKTI franchise into more settings and create additional products that reduce single-asset concentration.

What did the latest quarter show?

The first-quarter 2026 results showed strong demand and better adjusted profitability, but also higher manufacturing-related costs. CARVYKTI net trade sales reached approximately $597 million, up 62% from the first quarter of 2025. U.S. sales grew 36%, while ex-U.S. sales grew 222%, demonstrating that international launches are becoming a material growth engine.

Where did operating leverage appear?

Total revenue rose from $195.0 million in Q1 2025 to $305.1 million in Q1 2026. Operating loss improved only modestly, from $51.7 million to $49.8 million, because cost of collaboration revenue increased to $175.4 million from $69.5 million. Management attributed the increase to higher CARVYKTI sales, one-time capacity-expansion costs, and depreciation. R&D fell to $85.7 million from $101.9 million as major cilta-cel trials moved past intensive dosing phases, while pipeline spending rose. Selling and distribution expense increased to $50.1 million, reflecting commercial expansion.

Which strategic turning points shaped Legend Biotech?

Legend’s present economics are the result of a small number of decisions that converted a research organization into a commercial cell-therapy company. The most important turning point was not simply discovering cilta-cel; it was pairing the asset with a partner that could finance global development, execute registration programs, and build commercial access.

1. 2015
   Legend Biotech was incorporated, establishing a dedicated vehicle for cell-therapy development.
2. 2017
   Early clinical data for the BCMA-directed program attracted global attention and validated the underlying construct.
3. 2017-2018
   The Janssen collaboration supplied development capital, global infrastructure, and a profit-sharing model.
4. 2020
   Legend completed its Nasdaq listing, increasing access to public capital for manufacturing and pipeline investment.
5. 2022
   CARVYKTI received its first U.S. approval, shifting the company from development-stage to commercial execution.
6. 2024
   Earlier-line approvals expanded the eligible population and raised the importance of capacity and treatment-center throughput.
7. 2025-2026
   Global launches, manufacturing optimization, and pipeline diversification became the main strategic agenda.

What did the Janssen partnership change?

The partnership reduced the financing and commercialization burden that a standalone biotechnology company would otherwise bear. It also created shared economics and shared dependency. Legend benefits from Johnson & Johnson’s regulatory, medical, and commercial reach, but it does not control every launch, pricing, supply, or market-access decision. As of December 31, 2025, Legend had received $415 million of milestone payments and remained eligible for up to $935 million of future contractual milestones, including manufacturing, development, regulatory, and sales milestones.

What gives Legend Biotech a competitive advantage?

Legend’s moat is not a single patent or brand. It is a system combining clinical evidence, a differentiated BCMA-targeting construct, manufacturing know-how, global treatment-center relationships, and an established collaboration infrastructure. In cell therapy, the product and the production process are inseparable: reliability, turnaround time, release timing, and site coordination directly influence whether a physician can treat a patient.

How does manufacturing become part of the moat?

Autologous CAR-T starts with cells collected from an individual patient, followed by modification, expansion, quality testing, and return to the treatment center. Any failure or delay can have clinical consequences. Legend reported a 99% manufacturing success rate in Q1 2026 and more than 95% on-time order releases, indicating that operational quality is becoming a competitive asset rather than only a cost center. Manufacturing scale can also support margin expansion once fixed capacity is utilized more efficiently.

Which competitors create the most pressure?

How strong are Legend Biotech’s finances?

Legend has crossed an important threshold: revenue is now large enough to fund a growing share of operations, but the company has not yet demonstrated sustained IFRS profitability or positive free cash flow. FY2025 revenue rose to $1.03 billion from $627.3 million in FY2024. Operating loss narrowed to $136.5 million from $309.5 million, while adjusted net loss improved to $33.1 million from $188.8 million. IFRS net loss, however, widened to $296.8 million because unrealized foreign-exchange losses distorted the bottom line.

Is the balance sheet sufficient?

At December 31, 2025, Legend held $901.9 million of cash and cash equivalents plus $46.7 million of time deposits. Net cash used in operating activities was $100.2 million in FY2025, better than $144.0 million in FY2024 and $393.3 million in FY2023. At March 31, 2026, cash and time deposits were $834.6 million. Management said this supported runway beyond 2026 and expected company-wide adjusted profitability during 2026, but the Q1 cash decline shows that manufacturing expansion and pipeline work still consume capital.

What does profitability quality look like?

Who owns Legend Biotech, and why does governance matter?

Legend uses ordinary shares and American depositary shares, with each ADS representing two ordinary shares. The 2025 proxy statement reported 368,576,826 ordinary shares outstanding on May 7, 2025, including approximately 163,370,992 ordinary shares represented by ADSs. Each ordinary share carried one vote. This is simpler than a dual-class structure, but ownership influence remains important because GenScript is the company’s most significant shareholder and maintains related-party relationships with Legend.

How should investors interpret related-party exposure?

The annual report disclosed $26.6 million of 2025 sales and sales-based royalties from related parties and $14.3 million of purchases from related parties. These amounts are not large relative to total revenue, but they matter because they combine commercial relationships with a significant shareholder. Governance analysis should focus on board independence, conflict procedures, pricing discipline, and whether related-party arrangements remain strategically necessary as Legend scales.

Which pipeline opportunities could change the story?

The growth opportunity has two layers. The first is deeper CARVYKTI penetration through earlier treatment, broader geographic access, improved manufacturing throughput, and more treatment centers. The second is platform expansion beyond multiple myeloma. Legend’s 2026 investor materials highlight solid-tumor candidates, allogeneic approaches, autoimmune programs, and in-vivo CAR-T.

Why is in-vivo CAR-T strategically important?

Traditional autologous CAR-T is effective but operationally intensive. An in-vivo approach could avoid cell extraction and centralized manufacturing, shorten treatment time, and expand access. That opportunity also threatens the current moat if competitors achieve it first. Legend’s early LB2501 data therefore matter not only as a pipeline asset but as a strategic hedge against disruption of today’s production model. The company’s ASCO 2026 clinical update also highlighted early solid-tumor data for LB1908 and LB2102.

What risks could weaken Legend Biotech’s outlook?

Legend’s risk profile is concentrated and operational. The company’s official SEC filings page and 2025 annual report emphasize dependence on CARVYKTI, reliance on Janssen and other third parties, manufacturing complexity, clinical and regulatory uncertainty, pricing pressure, competition, intellectual-property exposure, and the legal structure of a Cayman Islands holding company with international operations. The risk is not merely that a clinical trial fails; it is that one weak link in a complex chain can affect patient access, revenue, cost, or confidence.

Which risk is most important?

The central risk is concentration around CARVYKTI combined with execution complexity. Strong clinical demand does not automatically become revenue if manufacturing slots, treatment-center capacity, reimbursement, or patient eligibility constrain throughput. Conversely, heavy capacity investment can pressure margins if demand develops more slowly than expected. The company must balance scarcity and overbuild while maintaining quality.

Why does Legend Biotech matter for valuation?

A conventional mature-company DCF is difficult because Legend is transitioning from loss-making commercialization to potential profitability while carrying substantial pipeline optionality. The near-term forecast should begin with CARVYKTI net trade sales, Legend’s collaboration-revenue share, cost of collaboration revenue, commercial expense, R&D, working capital, and manufacturing investment. The terminal value should not assume that early-stage programs succeed automatically.

Which variables drive intrinsic value most?

A useful scenario framework separates the existing CARVYKTI franchise from pipeline assets. The base business can be modeled using observable sales, collaboration economics, and expense trends. Pipeline programs should be probability-weighted by phase, indication, competitive context, and expected launch timing. The June 2026 financing activity also means per-share valuation should use a fully diluted share count rather than relying only on historical ADS data.

What is the key takeaway from Legend Biotech analysis?

Legend Biotech has already accomplished what many biotechnology companies never do: it helped create a globally important therapy, achieved commercial scale, and built enough revenue to approach adjusted profitability. FY2025 revenue exceeded $1 billion, CARVYKTI net trade sales reached about $1.9 billion, and Q1 2026 sales growth remained strong across the United States and international markets. Manufacturing performance also improved, with a 99% success rate and more than 95% on-time order releases.

What should students and investors monitor next?

The most decision-useful watch items are CARVYKTI net trade sales, U.S. versus ex-U.S. growth, manufacturing success and release timing, collaboration gross profit, operating cash flow, adjusted profitability, new treatment-center additions, progress in LB2102 and LB1908, proof-of-concept for LB2501, and changes in share count. Those measures collectively show whether Legend is evolving from a successful single-product biotechnology company into a durable, diversified cell-therapy platform.